Novel Targets, Enhanced Donor Transplantation, Show Promise in Blood Cancers

Stay tuned on this page for our upcoming coverage of the American Society of Clinical Oncology meeting 2010 focusing of hematologic malignancies.

Samuel Silver, MD, PhD

Samuel Silver, MD, PhD

Stay tuned on this page for our upcoming coverage of the American Society of Clinical Oncology meeting 2010 focusing of hematologic malignancies. To deliver the most insightful coverage, we have engaged nationally recognized hematology specialist, Samuel Silver, MD, PhD, Professor, Internal Medicine/Hematology-Oncology and Director of the University Cancer Center Network, University of Michigan Cancer Center, Ann Arbor, Michigan.

-Interviewed by Ron Piana

First up: An exclusive podcast interview-Dr. Silver elucidates the current trends and therapies for treating various blood cancers.

Next up: An expert perspective, gleaning the best hematologic highlights from this year’s meeting-Dr. Silver's clinical and research expertise spans bone marrow transplantation, malignant hematology, bleeding disorders, platelet dysfunction, myeloproliferative and myelodysplastic disorders and porphyria.

Watch this page for Dr. Silver's assessment of key sessions, abstracts, current therapies and future trends presented at the American Society of Clinical Oncology meeting 2010.

Related Videos
Experts on MM
Experts on multiple myeloma
Experts on MM
Daniel G. Stover, MD, suggests that stromal tumor infiltrating lymphocytes may serve as a biomarker of immune activation and can potentially help optimize therapy with microtubule-targeting agents for patients with metastatic breast cancer.
Experts on multiple myeloma
PRGN-3005 autologous UltraCAR-T cells appear well-tolerated and decreases tumor burden in a population of patients with advanced platinum-resistant ovarian cancer.
Related Content